6BrCaQ is a promising anti-cancer agent derived from novobiocin, which has been shown to inhibit Hsp90. 6BrCaQ was loaded into nanometer-scaled phospholipid vesicles (liposomes) suitable for drug delivery to solid tumors. The effective incorporation of the drug within the phospholipid bilayer was investigated by differential scanning calorimetry. Liposomal 6BrCaQ showed good activity on PC-3 cell lines in vitro in terms of apoptosis induction and cell growth arrest in G2/M. Liposomes containing 6BrCaQ were also shown to slow down migration of PC-3 cells in presence of chemokine ligand 2 and to synergize with doxorubicin. Several Hsp90 targeting molecules like Geldanamycin induce accumulation of Hsp70, leading to cytoprotection and often correlated with poor prognosis. In this study, we did not report any Hsp70 induction after treatment with liposomal 6BrCaQ but a decrease in Hsp90 and CDK-4 protein expression, indicating an effect on the chaperon machinery. Liposomal encapsulation of 6BrCaQ reveals promising anti-cancer effects and a better understanding of its mechanism of action.

Formulation and in vitro efficacy of liposomes containing the hsp90 inhibitor 6BrCaQ in prostate cancer cells / F. Sauvage, S. Franzè, A. Bruneau, M. Alami, S. Denis, V. Nicolas, S. Lesieur, F.X. Legrand, G. Barratt, S. Messaoudi, J. Vergnaud Gauduchon. - In: INTERNATIONAL JOURNAL OF PHARMACEUTICS. - ISSN 0378-5173. - 499:1/2(2016 Feb 29), pp. 101-109. [10.1016/j.ijpharm.2015.12.053]

Formulation and in vitro efficacy of liposomes containing the hsp90 inhibitor 6BrCaQ in prostate cancer cells

S. Franzè;
2016

Abstract

6BrCaQ is a promising anti-cancer agent derived from novobiocin, which has been shown to inhibit Hsp90. 6BrCaQ was loaded into nanometer-scaled phospholipid vesicles (liposomes) suitable for drug delivery to solid tumors. The effective incorporation of the drug within the phospholipid bilayer was investigated by differential scanning calorimetry. Liposomal 6BrCaQ showed good activity on PC-3 cell lines in vitro in terms of apoptosis induction and cell growth arrest in G2/M. Liposomes containing 6BrCaQ were also shown to slow down migration of PC-3 cells in presence of chemokine ligand 2 and to synergize with doxorubicin. Several Hsp90 targeting molecules like Geldanamycin induce accumulation of Hsp70, leading to cytoprotection and often correlated with poor prognosis. In this study, we did not report any Hsp70 induction after treatment with liposomal 6BrCaQ but a decrease in Hsp90 and CDK-4 protein expression, indicating an effect on the chaperon machinery. Liposomal encapsulation of 6BrCaQ reveals promising anti-cancer effects and a better understanding of its mechanism of action.
apoptosis; cell cycle; Hsp90; liposomes; migration; novobiocin analog
Settore CHIM/09 - Farmaceutico Tecnologico Applicativo
29-feb-2016
22-dic-2015
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0378517315304531-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.43 MB
Formato Adobe PDF
1.43 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/354530
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 21
social impact